Thu, 01 Feb 2024 16:09:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/hypoxia-guided-treatment-feasible-hpv-related-oropharyngeal-cancer/ Thu, 01 Feb 2024 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=116303 https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/decrease-in-head-and-neck-cancer-incidence-seen-during-pandemic/ Tue, 23 Jan 2024 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=116031 https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/oropharyngeal-cancer-worse-os-community-centers/ Fri, 19 Jan 2024 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=115967 https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/nasopharyngeal-carcinoma-treatment-loqtorzi-now-available/ Fri, 05 Jan 2024 15:40:00 +0000 https://www.empr.com/?p=213346 https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/toripalimab-nasopharyngeal-carcinoma-improves-pfs-os/ Thu, 21 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=114962 Adding toripalimab to first-line chemotherapy improved survival in patients with recurrent or metastatic nasopharyngeal carcinoma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/threshold-of-6-mm-on-retropharyngeal-lymph-node-predicts-pfs-in-nasopharyngeal-carcinoma/ Tue, 10 Oct 2023 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=111053 Minimal axial diameter ≥6 mm independently predicted progression-free survival in all patients, those with N0 to N1 disease.]]> https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/oral-health-overall-survival-head-neck-squamous-cell-cancer-treatment-risk/ Fri, 06 Oct 2023 15:01:00 +0000 https://www.oncologynurseadvisor.com/?p=111213 Certain aspects of oral health associated with overall survival in a study of patients with head and neck squamous cell carcinoma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/ngs-guided-treatment-is-feasible-for-platinum-refractory-head-and-neck-cancer/ Tue, 03 Oct 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=110889 Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.]]> https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/pet-ct-follow-up-may-confer-survival-benefit-in-head-and-neck-cancer/ Wed, 16 Aug 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=109914 Annual follow-up with ¹⁸FDG-PET/CT may improve survival, as compared to conventional follow-up, in patients with head and neck cancer.]]> https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/more-frequent-fosaprepitant-dosing-may-provide-some-benefits/ Fri, 04 Aug 2023 14:40:00 +0000 https://www.oncologynurseadvisor.com/?p=109621 Patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy are less likely to experience emesis when given fosaprepitant weekly rather than every 3 weeks, a study suggests.]]>